Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis

Masanori Hiramitsu 1,7*, Yasuhiro Shimada 1,2,3,4,5*, Junya Kuroyanagi 1, Takashi Inoue 7, Takao Katagiri 7, Liqing Zang 6, Yuhei Nishimura 1,2,3,4,5, Norihiro Nishimura 6 & Toshio Tanaka 1,2,3,4,5

1Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, Mie, Japan, 2Mie University Medical Zebrafish Research Center, Mie, Japan, 3Department of Systems Pharmacology, Mie University Graduate School of Medicine, Mie, Japan, 4Department of Bioinformatics, Mie University Life Science Research Center, Mie, Japan, 5Department of Omics Medicine, Mie University Industrial Technology Innovation Institute, Mie, Japan, 6Department of Translational Medical Science, Mie University Graduate School of Medicine, Mie, Japan, 7Central Laboratory, Pokka Sapporo Food & Beverage Ltd., Aichi, Japan.

Lemon (Citrus limon) contains various bioactive flavonoids, and prevents obesity and obesity-associated metabolic diseases. We focused on eriocitrin (eriodictyol 7-rutinoside), a powerful antioxidative flavonoid in lemon with lipid-lowering effects in a rat model of high-fat diet. To investigate the mechanism of action of eriocitrin, we conducted feeding experiments on zebrafish with diet-induced obesity. Oral administration of eriocitrin (32 mg/kg/day for 28 days) improved dyslipidaemia and decreased lipid droplets in the liver. DNA microarray analysis revealed that eriocitrin increased mRNA of mitochondrial biogenesis genes, such as mitochondria transcription factor, nuclear respiratory factor 1, cytochrome c oxidase subunit 4, and ATP synthase. In HepG2 cells, eriocitrin also induced the corresponding orthologues, and reduced lipid accumulation under conditions of lipid loading. Eriocitrin increased mitochondrial size and mtDNA content, which resulted in ATP production in HepG2 cells and zebrafish. In summary, dietary eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.

Non-alcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome, especially obesity, hyperlipidaemia and diabetes 1, and is now the most common liver disease in both adults and children worldwide 2. Regulation of lipid metabolism in the liver is critical to prevent the development of NAFLD, because NAFLD includes a spectrum ranging from simple steatosis to steatohepatitis (non-alcoholic steatohepatitis: NASH), which worsens to cirrhosis and sometimes hepatocellular carcinoma. The prevalence of NAFLD has been estimated as 17–33% in some countries 3, and ~10% of patients with NAFLD develop NASH and 8–26% of individuals with NASH progress to cirrhosis 4.

Recently, growing evidence from several epidemiological and clinical studies has indicated beneficial health effects of certain fruits and their components against obesity and its related diseases including dyslipidaemia. Citrus fruits, including lemon (Citrus limon Burm. f.), contain various polyphenols that have been shown to have several positive health effects, mainly involving glucose and lipid metabolism, in experimental animal models and humans 5–8. Of all the bioactive molecules of lemon, eriocitrin (eriodictyol 7-rutinoside) is a major flavonoid 9 with antioxidant activity 10. Eriocitrin has a suppressive effect on oxidative stress in diabetic rats 11 and a lipid-lowering effect in rats on high-fat and high-cholesterol diets 12. However, the mechanism of regulation of hepatic lipid metabolism by eriocitrin has yet to be elucidated.

To investigate the lipid-lowering mechanism of eriocitrin, we administered oral eriocitrin to a zebrafish model of diet-induced obesity (DIO-zebrafish) 13. Zebrafish is a small teleost that can be used for vertebrate models of human diseases 14–17. The high degree of genetic conservation in zebrafish compared with mammals contributes to its emergence as a model for obtaining insights into fundamental human physiology 18. In DIO-zebrafish, increases of body weight, plasma triglyceride (TG), and liver steatosis are highly consistent with obesity observed in humans and rodent models of DIO 13. The histology of adipose tissue, such as the liver and visceral fat, is also similar 13, as is the pathophysiological pathway of visceral fat, to that in human adipose tissues 13. In addition, we have demonstrated the anti-obesity mechanism of tomato 19 and green tea extract 20 using the DIO-zebrafish. Thus, DIO-zebrafish could be used to validate the mechanism of visceral adiposity and hepatic steatosis.
In this study, we conducted transcriptome analysis of eriocitrin feeding in DIO-zebrafish to investigate the mechanism of the lipid-lowering effect. We demonstrated that eriocitrin activated mitochondrial biogenesis in vivo and in vitro, which resulted in a protective effect against hepatic steatosis that was induced by DIO.

Results

Eriocitrin prevents diet-induced hyperlipidaemia and hepatic steatosis. We conducted eriocitrin feeding experiments to analyse their phenotypic effects on DIO-zebrafish for 4 weeks. The body weight of the overfeeding (OF) group was 1.6-fold higher ($P < 0.01$) than that of the normal feeding (NF) group at week 4 (Fig. 1a). The body length of the OF group was slightly longer than that of the NF group ($P < 0.05$, Fig. 1b). However, the body mass index (BMI), which was calculated by dividing the body weight (g) by the square of the body length (cm), was increased 1.4-fold in the OF compared with the NF zebrafish ($P < 0.01$; Fig. 1c). Plasma TG was also increased ($P < 0.05$) in the OF group (Fig. 1d). We fed eriocitrin-containing gluten granules to the DIO-zebrafish (32 mg/kg/day) for 4 weeks. Zebrafish ate all the eriocitrin-containing gluten granules within 5 min, and there was no appetite suppression during the feeding experiment (Supplementary Fig. S1). Eriocitrin administration did not result in a significant difference between the body weight and BMI (Fig. 1a and c), but eriocitrin significantly suppressed the increase in plasma TG in DIO-zebrafish ($P < 0.05$, Fig. 1d). However, the fasting blood glucose did not significantly differ between the eriocitrin-fed group and the others (Fig. 1e). Eriocitrin reduced lipid accumulation (red spots in Fig. 1f) in liver tissues more than overfeeding with vehicle gluten granules, which was consistent with the decrease in plasma TG.

Transcriptome analysis of the liver of eriocitrin-fed DIO-zebrafish. To reveal the therapeutic mechanism of eriocitrin against hepatic steatosis, we performed DNA microarray experiments on the liver tissues from eriocitrin-fed zebrafish. We compared the genome-wide expression profiles of zebrafish in the NF or OF groups with vehicle and eriocitrin (four groups in total) to identify genes related to improvement of hepatic steatosis. k-means/median clustering analysis defined 10 clusters, and revealed that clusters 7 and 10 were selectively altered in DIO-zebrafish fed with eriocitrin (OF + Erio group). The average expression levels of clusters 7 and 10 were significantly ($P < 0.001$) increased by eriocitrin feeding in the NF and OF groups. Expression levels were also significantly ($P < 0.001$) increased in the OF + Erio group compared with the NF + Erio group (Fig. 2a, 2b and Supplementary Fig. S2). These findings implied that these clusters were involved in the therapeutic mechanism of eriocitrin. In total, 282 probes of these clusters corresponded to 152 human orthologues (Supplementary Table S1).

Analysis of the genes with altered expression by Gene Ontology (GO) category using GOSTat2 revealed that 20 of their 150 human orthologues (13.1%) were involved in ATP synthesis and mitochondrial electron transport (Table 1). The GO analysis was conducted in the category of biological process, and $P < 0.01$ was considered to be significant.

We conducted gene set enrichment analysis (GSEA) of DIO-zebrafish fed with gluten and eriocitrin. GSEA is a powerful method that can analyse expression of every functional group of genes, and it has been used to clarify the mechanisms of various clinical conditions and effects. GSEA showed that expression of 15 gene sets was significantly higher (false discovery rate $< 0.2$) in zebrafish fed with eriocitrin (Supplementary Table S2). GSEA revealed that the gene set “HUMAN_MITODB_6_2002” was significantly upregulated in DIO-zebrafish fed with an eriocitrin diet (Fig. 2c). HUMAN_MITODB_6_2002 is activated by peroxisome proliferator activated receptor γ coactivator 1 (PPARGCI) and highly correlated with mitochondrial functions. GO analysis and GSEA suggested that eriocitrin ameliorated hepatic steatosis by activating mitochondrial functions and ATP synthesis.

To confirm the results of GSEA analysis, we conducted quantitative (q)RT-PCR analysis of genes related to lipid metabolism and mitochondrial biogenesis, including genes in DNA microarrays (Table 2). Eriocitrin feeding significantly upregulated the mRNA level of lipid metabolism genes, pparab (zebrafish homologue of human PPARA), acox1 and acadm (Fig. 3a). In addition, pparg1al (zebrafish homologue of human PPARC1A, also called PGC-1α), a gene involved in fatty acid oxidation, showed a nonsignificant trend towards ($P = 0.36$) increased expression with eriocitrin feeding (Table 2). As for mitochondrial genes, an eriocitrin diet significantly upregulated the mRNA levels of tfam and nrf1, which are mitochondrial biogenesis markers, and cox4i1 and atp5j, which are involved in ATP synthesis (Fig. 3c).

Eriocitrin induces gene expression related to mitochondrial function in HepG2 cells and reduced lipid accumulation. To examine whether the alterations in gene expression detected in eriocitrin-fed zebrafish could be extrapolated to human liver, we treated HepG2 human hepatocarcinoma cells with eriocitrin for 48 h. As for the genes involved in lipid metabolism, qRT-PCR showed that eriocitrin increased the mRNA levels of ACADM (Fig. 3b) in a dose-dependent manner. Unlike the results with zebrafish, PPARA and ACOX1 were not affected by eriocitrin exposure. As for mitochondrial gene expression, eriocitrin increased TFAM, COX4I1 and ATP5J expression in a dose-dependent manner (Fig. 3d), which was similar to the results observed for the zebrafish model (Fig. 3c).

To investigate the ability of eriocitrin to prevent lipid accumulation, the HepG2 cells were incubated in a medium containing palmitate to induce lipid-overloading conditions. Cultured HepG2 cells were treated with eriocitrin (30 μM) for 2 days and then exposed to 400 μM palmitate with or without eriocitrin. The total lipid levels were detected by Oil Red O staining. Co-treatment of HepG2 cells with palmitate and eriocitrin (Pal + Erio) significantly prevented cellular lipid accumulation ($P < 0.05$, Fig. 3e and f). qRT-PCR analysis of the same genes in lipid-loaded HepG2 cells (Supplementary Figs. S3 and S4) showed similar gene expression patterns to those that were observed from the DIO-zebrafish (Fig. 3a and c).

Eriocitrin activates mitochondrial biogenesis. From the results of the transcriptome analysis of eriocitrin treatment, we hypothesized that eriocitrin activates mitochondrial biogenesis. Thus, we performed mitochondrial staining using MitoTracker Red CMXRos, which stained the perinuclear region of the mitochondria. After 48 h incubation with 10 μM eriocitrin, the mitochondrial mass of HepG2 was significantly increased compared with that observed with vehicle treatment (Fig. 4a, b). The mitochondrial biogenesis process involves expression of nuclear-encoded proteins that are essential for replication of mtDNA. We measured mtDNA copy numbers by qRT-PCR. To assess mtDNA content per cell, we measured the number of copies of well-conserved single-copy genes. PK was used as a marker for nuclear DNA and CYTB for mtDNA, as described previously. Treatment with eriocitrin for 72 h significantly increased the mtDNA content in a dose-dependent manner, which corresponded to results observed from the image analysis (Fig. 4c). Subsequently, activation of mitochondrial biogenesis resulted in an increase in intracellular ATP production by eriocitrin treatment (Fig. 4d).

To evaluate the effects of eriocitrin on whole animal physiology, we started eriocitrin exposure at 4 dpf zebrafish for 72 h. At 7 dpf, addition of 10 μM eriocitrin to the breeding water also increased the total ATP content of zebrafish (Fig. 4e), which was consistent with the results for HepG2 cells (Fig. 4d).
Figure 1 | Assessment of body weight and length, plasma TG, and hepatic steatosis in zebrafish overfed with eriocitrin. (a) Average body weight; (b) average body length; and (c) BMI in each group during 4 weeks feeding. Each group contained 10 fish. All values are mean ± SEM. *P < 0.05, **P < 0.01 versus vehicle in the NF group. (d) Plasma TG levels in each group. Four weeks’ administration of eriocitrin reduced plasma TG in the OF group. Values are mean ± SEM; n = 10. *P < 0.05. (e) Fasting blood glucose in each group. Values are mean ± SEM; n = 10. (f) Oil Red O staining of liver sections. Eriocitrin reduced the number of lipid droplets (red) compared with the OF group. Erio: eriocitrin.
Figure 2 | Analysis of DNA microarray data. (a) Clustering analysis of DNA microarrays and (b) the average expression levels of clusters 7 and 10. (c) GSEA plots showed that expression of a mitochondrial gene module was more enriched in the OF + Erio group compared with the OF group.
Discussion

A lot of research has recently been conducted regarding the mechanism of the development of NAFLD, and a strong correlation has been observed between this mechanism and the origin of metabolic syndrome, mainly obesity. However, the genesis of obesity is multifactorial, and there is evidence that reduced energy expenditure, in particular reduced capacity to utilize fat for metabolic fuel, is an important factor, particularly in the weight-reduced state26. In obese people, therapeutics often target the mitochondria of metabolically active tissues such as skeletal muscle, liver, adipose tissues, and the heart47. There is also growing evidence that mitochondria have a key role in NAFLD26,27. Our studies demonstrated that eriocitrin suppressed the increase in serum TG and ameliorated hepatic steatosis through activation of mitochondrial biogenesis in DIO-zebrafish.

Eriocitrin is a stronger antioxidant than the other citrus flavonoid compounds and is abundant in lemon and lime28, with safety proven by the lack of developmental toxicity in zebrafish (Supplementary Figs. S5 and S6). In addition, a rat feeding test revealed that lemon flavonoids containing 33% eriocitrin could be administered at ≈2 g/kg/day for 4 weeks without causing any toxicological phenotypic changes, including body weight, feeding volume, urine, haematological and biochemical parameters, organ weight, and histology (data not shown). There was no phenotypic change at ≈2 g/kg/day. This finding suggests that the lipid-lowering action of eriocitrin might be limited in lipid dysregulation (e.g., hyperlipidaemia). For example, naringin (a flavonoid found in citrus fruits) has been shown to also improve lipid profiles in a high-fat diet-induced model of obesity in rats, but there was no difference in the treatment group upon normal feeding19. Previous studies have focused on the lipid-lowering effects of eriocitrin on antioxidant defence mechanisms10,11 but have provided little information on its effects on mitochondria. In our previous study using high-fat diet mice, crude extracts of the polyphenol fraction from lemon peel also ameliorated the symptoms of the metabolic syndrome, including dyslipidaemia, with expression of Ppara and Acox1 (mitochondrial β-oxidation enzyme) in the liver26. Eriocitrin also increased ppara and other β-oxidation enzyme genes, acox1 and acadm, suggesting that eriocitrin is the main antidyslipidaemic component in lemon polyphenols. Additionally, PPAR agonist ameliorated NAFLD in mice by modulating the genes for enzymes involved in fatty acid metabolism, including Acox1 and Acadm20, which was similar to eriocitrin-induced expression of PPARA.

Eriocitrin also increased the expression of genes involved in mitochondrial biogenesis (NRF1 and TFAM) and ATP synthesis (ATPSJ and COX41). NRF1 activates the transcription of several nuclear-encoded genes, especially mtDNA, and its liver-specific inactivation leads to hepatic steatosis and neoplasia48, indicating that the therapeutic mechanism of eriocitrin is through NRF1 induction. PPARC1A regulates NRF1-dependent transcription49 and increases expression of nuclear and mitochondrial-encoded genes of oxidative metabolism (lipid oxidation, and electron transport complexes) to promote mitochondrial biogenesis50. In addition, dietary restriction also increases mitochondrial respiration, with gene expression for PPARGC1A, NRF1 and cytochrome C oxidase subunit IV49, which appears to be consistent with our results for eriocitrin. PPARGC1 also has a role in this pathway by activating NRF1 to induce expression of TFAM, which is important to the transcription of mtDNA50,51. Thus, in DIO-zebrafish and HepG2 cells, eriocitrin may also activate or induce PPARGC1, subsequently promote NRF1 and TFAM expression to induce mitochondrial biogenesis and energy expenditure, and finally ameliorate hepatic steatosis. In spite of the eriocitrin-induced activation of mitochondria, we could not detect any antioxidant activity by DNA microarray analysis, except for upregulation of prdx3. Although oxidative phosphorylation is a vital part of the ATP production induced by eriocitrin, it also produces reactive oxygen species such as superoxide and hydrogen.
perroxide. This leads to propagation of free radicals, which damage cells and contribute to inflammatory disease, NASH and, possibly carcinogenesis. We hypothesized that eriocitrin-induced prdx3 expression could prevent this pathway as an antioxidative mechanism. Oxidative stress coupled with hepatocyte apoptosis is believed to play a pivotal role in the pathogenesis of NAFLD. In addition, emerging data now suggest that hepatocyte apoptosis may be a key component of the “second hit” involved in the progression of simple steatosis to NASH. In this context, several studies reported that antioxidants attenuate oxidative stress and hepatic steatosis; however, we could not detect the antioxidant properties of eriocitrin in the current study.

To predict the site of action of the therapeutic effects of eriocitrin, we conducted Sub-Network Enrichment Analysis (SNEA) of our DNA microarray data. SNEA could identify key molecules regulating the expression of the genes involved in lipid metabolism and mitochondrial biogenesis. Although eriocitrin may influence multiple lipid-metabolizing pathways, similar to other polyphenols, we found

| Gene symbol | Gene ID | qRT-PCR | DNA microarray |
|-------------|---------|---------|---------------|
| pparab      | 557714  | 0.37 ± 0.05 | nd |
| acox1       | 449662  | 0.64 ± 0.12 | 1.04 ± 0.21 |
| acadm       | 406283  | 0.73 ± 0.14 | 0.98 ± 0.11 |
| cox4i1      | 326975  | 0.59 ± 0.05 | 1.01 ± 0.03 |
| atp5j       | 406599  | 0.72 ± 0.06 | 1.06 ± 0.10 |
| ppargc1a    | 553418  | 0.27 ± 0.18 | nd |
| nrf1        | 64604   | 1.31 ± 0.32 | 0.94 ± 0.16 |
| tfam        | 571106  | 0.42 ± 0.02 | 0.78 ± 0.02 |

All values are mean ± SEM; n = 4 or 5, *P < 0.05, **P < 0.01.

Figure 3 | qRT-PCR of genes related to lipid metabolism and mitochondrial functions, and eriocitrin reduced lipid accumulation in HepG2 cells. To confirm the DNA microarray analyses, qRT-PCR was conducted. Genes related to lipid metabolism in zebrafish (a) and HepG2 cells (b). Genes related to mitochondrial biogenesis and respiratory function in zebrafish (c) and HepG2 cells (d). All values are means ± SEM; n = 5, *P < 0.05, **P < 0.01. (e) Oil Red O staining of HepG2. (f) Absorbance of Oil Red O during lipid accumulation. Eriocitrin reduced lipid accumulation in palmitate-stimulated HepG2. All values are means ± SEM; n = 8, *P < 0.05.
Figure 4 | Eriocitrin increased mitochondrial biogenesis and ATP production. (a) Eriocitrin (10 μM) increased mitochondrial size (red) of HepG2 cells using MitoTracker Red CMXRos staining. Blue colour represents the nucleus (Hoechst 33342). (b) Quantitative analysis of mitochondrial staining. (c) Quantification of mtDNA was accomplished by calculating the ratio of CYTB to nuclear PK and expressing it as mtDNA copy number per cell. (d), (e) ATP quantification with eriocitrin administration. Upon 72 h administration of eriocitrin, there were increased intracellular ATP in HepG2 cells (d) and systemic ATP of 7 dpf zebrafish (e). All values are mean ± SEM; n = 8, *P < 0.05, **P < 0.01.
Table 3 | Prediction of eriocitrin mechanism using SNEA

| Gene set seed | Name                                      | Total # of neighbours | # of measured neighbours | Measured neighbours                                                                 | Median change | P value |
|---------------|-------------------------------------------|-----------------------|--------------------------|-------------------------------------------------------------------------------------|---------------|---------|
| RXR           | Retinoid X receptor                       | 248                   | 68                       | APOA4, VEGFA, DDAH1, LCN2, FGFR1, CAV1, SCARB1, ABCC2, CYP27A1, FGB, HMOX1, MGP, ACOX1, CA2, NR1D1, ARG2, CYP8B1, VDR, ABCG5, LPL, CEBPA, PTPN6, RBP1, APOA1, CETP, DBI, FOS, MYOD1, ANGPTL3, THR8, BCL2, EGFR, BCI2, NDRG1, SLCA2A, ACADM, SLCA2A, ACLY, ACO1, PTH1R, CYP4A11, FABP1, GATA6, Mef1, RXR, COL1A2, PLIN2, SCP2, SLCA2A, CRABP1, CYB, DUSP1, CCND1, ACACB, TRB3, CYB, ANGPTL4, ABCA1, NR1H4, NR1H3, HAND2, LDLR, SLCA3A1, MAF, DCN, EGR1, RETN, SLCA2A, CAV1, PTGDS, CEBPB, ABCA1, FABP1, CETP, ACS52, HMGCS1, DBI, LPIN1, IRS2, PFKFB1, ACACB, ALDH1A2, INSIG1, VEGFA, PKLR, PDX1, SLCA2A, FDP5, HK2, RETN, ACY, FADS2, ELOVL5, HMOX1, LPL, AR, HNF4A, Lipe, LIPC, CYP8B1, ACSL1, GNA12, GPS3, PGD, CASP2, ID1H1, HSD17B7, COL6A1, TRB3, DHCR7, GPAM, SP1, HDC, IDIR, SCARB1, BAX, CEBPA | -1.017        | 0.004   |
| SREBF1        | Sterol regulatory element binding         | 134                   | 50                       | SLC2A2, CAV1, PTGDS, CEBPB, ABCA1, FABP1, CETP, ACS52, HMGCS1, DBI, LPIN1, IRS2, PFKFB1, ACACB, ALDH1A2, INSIG1, VEGFA, PKLR, PDX1, SLCA2A, FDP5, HK2, RETN, ACY, FADS2, ELOVL5, HMOX1, LPL, AR, HNF4A, Lipe, LIPC, CYP8B1, ACSL1, GNA12, GPS3, PGD, CASP2, ID1H1, HSD17B7, COL6A1, TRB3, DHCR7, GPAM, SP1, HDC, IDIR, SCARB1, BAX, CEBPA | -1.055        | 0.005   |
| STAT6         | Signal transducer and activator of        | 119                   | 20                       | CAV1, BCL2, BAX, IGFBP1, COL1A2, BCI2, AICDA, AGT, IRS2, SOCS3, MUC5AC, IGFI, CDKN1B, MUC1, KLCA1, EGR1, MAF, PML, VCA1, NFl3 | -1.450        | 0.006   |
| CDX2          | Caudal type homeobox 2                    | 64                    | 11                       | IRS2, HNF1A, CDH17, FABP2, HNF4A, VDR, ACAT2, SP1, HBEFG, LYP1A, BCL2 | 1.328         | 0.007   |
| MAPK11        | Mitogen-activated protein kinase 11       | 36                    | 11                       | SCARB1, BAX, BCI2, HMOX1, VDR, CEBPD, PRDX1, CAV1, CEBPB, EGR1, CCND1, CEBPA | 1.025         | 0.007   |
| Luteinizing hormone |                               | 69                    | 15                       | LDIR, SCARB1, EGFR, AREG, CEBPD, RETN, C13orf15, KDR, IGFBP5, ANX5, FLT1, IGFBP1, SGK1, PSEN1, CEBPB | -1.238        | 0.007   |
| NKX2.5        | NK2 homeobox 5                            | 52                    | 14                       | CALR, TIL1, CTNNB1, GATA4, PIK32, ACTC1, DIO2, MF2A, AICACB, T, PLOD1, MYOD1, HOX, ACTA2 | -1.360        | 0.008   |
| HEY1          | Hairy/enhancer-of-split related with       | 23                    | 11                       | MDM2, RUNX2, ID1, ACT2, KDR, GATA4, GATA6, MYF5, OCLN, AR, PRODH2 | -1.342        | 0.008   |
| Runt          | Runt-related transcription factor         | 50                    | 9                        | BCL2, C13orf15, LGALS3, CEBPD, TGFB1, BTG2, SP1, IL7R, RUNX2 | -1.368        | 0.009   |
that two lipid metabolism pathways, retinoid X receptor (RXR) and sterol regulatory element-binding transcription factor 1 (SREBF1) pathways were significantly \((P < 0.01)\) influenced by eriocitrin feeding (Table 3, underlined). Eriocitrin suppressed the RXR pathway, which was consistent with its antidiabetic effects. PPARs regulates genes involved in lipid metabolism via heterodimerization with RXR as an obligate partner\(^{42,43}\), suggesting interaction between eriocitrin and RXR, especially RXR-\(\alpha\). RXR antagonist HX531 has been reported to ameliorate obesity\(^{6,44}\), therefore, we hypothesize that eriocitrin acts as an RXR antagonist in liver adiposity. In fact, daidzein (a flavonoid found in soybeans) has been shown to suppress RXR-\(\alpha\) expression\(^{46}\) and improve lipid metabolism\(^{65}\), which is in accordance with the prediction of RXR enrolment in eriocitrin pathways. Eriocitrin was also predicted to downregulate the SREBF1 pathway (Table 3). Srebf1 is induced by heterodimerization of liver X receptor (LXR) and RXR\(^{48}\), supporting the RXR hypothesis of eriocitrin described above. In addition, resveratrol, a polyphenol present in grapes and peanuts, has been reported to alleviate alcholic fatty liver by inhibiting Srebf1 expression via the Forkhead box protein \(01\) (Fox01) signalling pathway\(^{49}\). fox01 was also decreased by eriocitrin in DNA microarray data, implying a similar mechanism for eriocitrin and resveratrol.

In conclusion, our observations using DIO-zebrafish and cultured human cells demonstrate a novel mechanism of powerful lipid-lowering activity of eriocitrin. Steatohepatitis is sometimes caused by hepatic steatosis and decreases the activity of respiratory chain complexes and impairs the ability to synthesize ATP in patients\(^{50}\). Eriocitrin promotes mitochondrial \(\beta\)-oxidation and biogenesis and ameliorates high-fat-diet-induced hepatic steatosis.

**Methods**

**Ethical approval.** This study has been approved by the Ethics Committee of Meisei University, and was performed according to Japanese animal welfare regulation ‘Act on Welfare and Management of Animals’ (Ministry of Environment of Japan) and complied with international guidelines.

**Preparation of eriocitrin.** Eriocitrin was prepared from lemon peel using the modified method of Miyake et al.\(^{51}\). The lemon peel was extracted using deionized water. The extract was applied to an Amberlite XAD-16 column (Rohm and Haas Philadelphia, PA, USA). The column was washed with water, and eluted with 40% ethanol. The eluate was concentrated under reduced pressure and crude lemon flavonoids were obtained. Eriocitrin was prepared from crude flavonoids using preparative HPLC (LC-8A; Shimadzu, Kyoto, Japan) using a YMC-Pack ODS column \((50 \times 250 \text{ mm; YMC, Kyoto, Japan})\). The purity was determined as >96% using HPLC (LC-10A; Shimadzu).

**Feeding zebrafish and experimental design.** Adult zebrafish (AB line; Zebrafish International Resource Center, Eugene, OR, USA) were kept at 28°C under a 14 h light: 10 h dark cycle, and water conditions of environmental quality were maintained as previously described\(^{47}\). Zebrafish were assigned into each dietary group for 2 or 4 weeks with fish per 1.7-L tank. From 3.5 mpf, zebrafish in the OF group were fed three times per day with Artemia (60 mg cysts/fish/day; Miyako Kagaku, Tokyo, Japan), and the control group were fed once daily in the morning \((-09:00\) h), as described previously\(^{52}\). Compared with flake foods that have also been used to feed zebrafish\(^{53}\), the amount of fat and protein in Artemia are higher and lower, respectively, whereas the amount of carbohydrate is comparable\(^{54}\). Zebrafish fed 5 or 60 mg/day freshly hatched Artemia consumed about 80% and 50% of the provided Artemia, respectively, translating to 20 and 150 mg cal. Maintenance energy requirement for zebrafish is <30 cal\(^{55}\), therefore, it seemed reasonable to induce DIO-zebrafish by feeding zebrafish with 5 or 60 mg/day Artemia. Eriocitrin was prepared from crude flavonoids using preparative HPLC (LC-8A; Shimadzu) using a YMC-Pack ODS column \((50 \times 250 \text{ mm; YMC, Kyoto, Japan})\). The purity was determined as >96% using HPLC (LC-10A; Shimadzu).

**Measurement of body weight, plasma TG and blood glucose.** The body weight and length of zebrafish were measured weekly throughout the study as described previously\(^{56}\). For the blood chemistry analyses, zebrafish were deprived of food overnight and blood was withdrawn from the dorsal artery by a heparinized glass capillary needle (GD-1; Narishige, Tokyo, Japan) at the indicated times. Blood glucose\(^{57}\) and plasma TG\(^{58}\) were measured as described previously.

**Oil Red O staining.** Liver tissues were collected from zebrafish by surgical manipulation under a stereoscopic microscope (MZ16FL; Leica Microsystems, Wetzlar, Germany). The livers were fixed in Histo-Fresh (Falma, Tokyo, Japan) and embedded in Tissue-Tek (Sakura Finetek, Tokyo, Japan) and dissected in a cryostat (Microm HM-550; Thermo Fisher Scientific, Waltham, MA, USA). The sections were stained with Oil Red O (Wako Pure Chemical Industries) as described previously\(^{59}\). Liver glyco- zytes and Oil Red O-stained lipids were imaged using confocal microscopy (Zeiss, Thornwood, NY, USA). Intracellular lipid accumulation was quantified by measurement of OD\(_{520}\) using the Victor2 multilabel plate reader (PerkinElmer, Boston, MA, USA).

**DNA microarray experiments.** Liver tissues were collected from DIO-zebrafish for each experimental condition. Livers were fixed in RNA later (Applied Biosystems, Foster City, CA, USA) at 4°C for 1 day. The liver tissues were immersed in 1 ml Isogen (NipponGene, Tokyo, Japan) and homogenized using the Mixer Mill MM 300 (Retsch, Haan, Germany) with 5-mm zirconia beads (BioMedicalScience, Tokyo, Japan) for 3 min at 25 Hz. After homogenization, total RNA was extracted according to the protocol for Isogen, in combination with the clean-up protocol of the RNaseasy Mini Kit (Qiagen, Hilden, Germany). The DNA microarray experiments were conducted using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Santa Clara, CA, USA) and G2518A Agilent Zebrafish Whole Genome Oligo Microarrays (Agilent Technologies), as previously described\(^{59}\). The hybridized microarrays were scanned (Agilent G2565BA microarray scanner) and quantified using Feature Extraction software (Agilent Technologies). One-way analysis of variance (ANOVA) was performed to identify differentially expressed probes \((P < 0.01)\). k-means clustering was conducted using MultiExperiment Viewer MeVe4, a microarray analysis software tool\(^{60}\). The probes of human orthologues using the Life Science Knowledge Bank (World Fusion, Tokyo, Japan). GSEA and SNEA were conducted using Pathway Studio 7 (Ariadne Genomics, Rockville, MD, USA).

**Cell culture and treatment.** HepG2 human hepatocarcinoma cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA), supplemented with 100 \(\mu\)g/ml streptomycin sulphate (Sigma–Aldrich), 100 u/ml penicillin G (Sigma–Aldrich) and 10% (v/v) foetal bovine serum (FBS; Invitrogen), and maintained at 37°C in an atmosphere of 5% CO\(_2\) and 95% air. Sodium palmitate was dissolved in preheated 0.1 N NaOH and diluted in DMEM containing 1.76% (w/v) bovine serum albumin (BSA), to give a final palmitate concentration of 400 \(\mu\)M as described previously\(^{61}\). Palmitate was administered after 48 h treatment with eriocitrin.

**qRT-PCR of zebrafish and cultured cells.** For liver tissues of adult zebrafish, total RNA of each sample was purified as described above. For young zebrafish, eight fish were homogenized in RLT buffer using the Mixer Mill 300. Total RNA was purified using the RNeasy Mini Kit (Qiagen), according to the manufacturer’s protocol. For cultured cells, total RNA was also purified using the RNeasy Mini Kit. First-strand cDNA was prepared with 200 ng total RNA using the Super Script III First-strand System (Life Technologies, Gaithersburg, MD, USA) with random primers (Life Technologies). qRT-PCR was performed with Power SYBR Green Master Mix (Applied Biosystems) in triplicate, according to the manufacturer’s protocol. The sequences of the primers are shown in Supplementary Table S3. The oligonucleotides of these primers were synthesized by Life Technologies.

**qRT-PCR for measurement of mtDNA.** mtDNA was extracted using phenol/ chloroform precipitation and stored in water at \(-80°C\) until analysis\(^{62}\). Purity and concentration of DNA recovered were determined using a NanoDrop spectrophotometer. Real-time PCR was performed with Power SYBR Green PCR mix (Applied Biosystems) in an ABI 7300 Real Time PCR System (Applied Biosystems). Quantification of mtDNA was accomplished by calculating the ratio of a mitochondrial-encoded gene \((\text{Cytb})\) to a nuclear-encoded gene \((\text{Ppck})\), and expressing it as mtDNA copy number per cell.

**Measurement of mitochondrial size.** HepG2 cells were seeded at 5 \(\times 10^4\) cells/ml in tissue-culture-treated \(\mu\)-slide eight-well plates (ibidi, Martinsried, Germany), and incubated for 48 h with or without eriocitrin. The cells were stained with MitoTracker Red CMXRos (Molecular Probes, Eugene, OR, USA) and Hoechst 33342 (Dojindo, Tokyo, Japan) to a nuclear-encoded gene \((\text{Ppck})\), to a nuclear-encoded gene \((\text{PK})\), and expressing it as mtDNA copy number per cell.
For the cell-based study, HepG2 cells were seeded in 96-well microplates at 2.0 x 10^4 cells/well in 100 μl growth medium. Cells were incubated at 37°C for 3 days with eriocitrin. Before the ATP assay started, cell numbers in each well were measured using Calcein-AM (Dojindo), according to the manufacturer’s instructions. After that, the ATP measurements (CellTiter-Glo luminescent cell viability assay) were performed according to the manufacturer’s instructions. Fluorescence and luminescence were measured by Victor2 fluorescence plate reader (PerkinElmer).

Eriocitrin toxicity in zebrafish. Zebrafish embryos were exposed to eriocitrin from 6 hpf to 5 dpf. The number of survivors was counted under a MZ16F stereoscopic microscope (Leica Microsystems). One hour before evaluation of locomotor activity, a fish was removed from each experimental unit and placed in a well with 50 μl of E3 medium in a 96-well, clear-bottom plate for acclimatization. The fish were then video-recorded for 15 min. The resulting footage was evaluated to measure the swimming distance using the EthoVision XT system ver8.0 (Noldus Information Technology, Wageningen, The Netherlands) as described previously.

Statistical analysis. All data were represented as mean ± SEM. Differences between the two groups were examined for statistical significance using Student’s t test. For multiple comparisons, we used one-way ANOVA followed by Bonferroni–Dunn multiple comparison. P < 0.05 was considered to denote statistical significance.

1. Pagano, G. et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35, 367–372 (2002).
2. Moore, J. B. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 69, 211–220 (2010).
3. Raszeja-Wyszomirska, J., Lawniczak, M., Marlicz, W., Miezynska-Kurtycz, J. & Milkiewicz, P. [Non-alcoholic fatty liver disease—new view], Pol Merkur Lekarski 24, 555–558 (2006).
4. Wree, A., Kahraman, A., Gerken, G. & Canbay, A. Obesity affects the liver—the two groups were examined for statistical significance using Student’s Statistical analysis.
5. Jung, U. J., Lee, M. K., Jeong, K. S. & Choi, M. S. The hypoglycemic effects of eriocitrin. Before the ATP assay started, cell numbers in each well were measured using Calcein-AM (Dojindo), according to the manufacturer’s instructions. After that, the ATP measurements (CellTiter-Glo luminescent cell viability assay) were performed according to the manufacturer’s instructions. Fluorescence and luminescence were measured by Victor2 fluorescence plate reader (PerkinElmer).
6. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545–15550 (2005).
7. Gonzalez-Molina, E., Dominguez-Perles, R., Moreno, D. A. & Garcia-Viguera, C. The hypoglycemic effects of eriocitrin. Before the ATP assay started, cell numbers in each well were measured using Calcein-AM (Dojindo), according to the manufacturer’s instructions. After that, the ATP measurements (CellTiter-Glo luminescent cell viability assay) were performed according to the manufacturer’s instructions. Fluorescence and luminescence were measured by Victor2 fluorescence plate reader (PerkinElmer).
8. Fukuchi, Y. et al. Lemon Polyphenols Suppress Diet-induced Obesity by Up-Regulation of mRNA Levels of the Enzymes Involved in beta-Oxidation in Mouse White Adipose Tissue. J Biochem Tissue. J Nutr 43, 201–209 (2008).
9. Oka, T. et al. Mechanisms controlling mitochondrial biogenesis and oxidative stress in diabetic rats. J Neurochem 107, 8–14 (2008).
10. Miyake, Y. et al. Mitochondrial transcriptome analysis of anti-fatty liver action by Campari. PLoS Genet 3, e199 (2007).
11. Zebrafish beta-adrenergic receptor mRNA expression and control of pigmentation. Zebrafish (Danio rerio). 8, 1464–1465 (2007).
12. Miyake, Y., Yamamoto, K., Morimitsu, Y. & Osawa, T. Isolation of C. glucoxyflavone from lemon peel and antioxidative activity of flavonoid compounds in lemon fruit. J Agric. Food Chem. 45, 4619–4623 (1997).
13. Alam, M. A. et al. Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, high fat diet-fed rats. Nutrients 5, 637–650 (2013).
14. Duval, C., Fruchart, J. C. & Staels, B. PPAR alpha, fibrates, lipid metabolism and nonalcoholic steatohepatitis. Hepatology 41, 286–303 (2005).
15. Tanaka, T. The hypoglycemic effects of eriocitrin. Before the ATP assay started, cell numbers in each well were measured using Calcein-AM (Dojindo), according to the manufacturer’s instructions. After that, the ATP measurements (CellTiter-Glo luminescent cell viability assay) were performed according to the manufacturer’s instructions. Fluorescence and luminescence were measured by Victor2 fluorescence plate reader (PerkinElmer).
16. Kinkel, M. D. & Prince, V. E. On the diabetic menu: zebrafish as a model for diabetes. Diabetes 51, 3249–3251 (2002).
17. Scarpulla, R. C. Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene 286, 81–89 (2002).
18. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545–15550 (2005).
19. Berthiaume, J. & Wallace, K. B. Perfluorooctanoate, perfluorooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol Lett 129, 33–32 (2002).
20. Miyake, Y. et al. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 17, 446–452 (2010).
21. Clapham, J. C. & Storlien, L. H. The fatty acid oxidation pathway as a therapeutic target for insulin resistance. Expert Opin Ther Targets 10, 749–757 (2006).
22. Bournat, J. C. & Brown, C. W. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci U S A 104 (2007).
23. Beissbarth, T. & Speed, T. P. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 20, 1466–1467 (2004).
This work was supported in part by KAKENHI (24590318), the New Energy and Industrial Technology Development Organization, and the Japan Chemical Industry Association. We would like to thank K. Nishiguchi and M. Ariyoshi for their experimental assistance and R. Ikeyama for secretarial assistance.

Acknowledgments
This work was supported in part by KAKENHI (24590318), the New Energy and Industrial Technology Development Organization, and the Japan Chemical Industry Association. We would like to thank K. Nishiguchi and M. Ariyoshi for their experimental assistance and R. Ikeyama for secretarial assistance.

Author contributions
M.H. and Y.S. conducted animal and cell-based experiments and prepared the manuscript. J.K. prepared the zebrafish. J.K. and Z.L. also conducted animal experiments. T.I. and T.K. purified eriocitrin and evaluated its purity. Y.N. conducted statistical analyses. T.K., N.N. and T.T. planned the experiments. T.T. modified the manuscript.

Additional information
Supplementary information accompanies this paper at http://www.nature.com/scientificreports

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Hiramitsu, M. et al. Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis. Sci. Rep. 4, 3708; DOI:10.1038/srep03708 (2014).

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0